Origin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure

Journal of Virology

Volumn 76, Issue 14, 2002, Pages 7000-7009

  Kijak, Gustavo H ^a   Simon, Viviana ^c   Balfe, Peter ^d   Vanderhoeven, Jeroen ^c   Pampuro, Sandra E ^a   Zala, Carlos ^b   Ochoa, Claudia ^b   Cahn, Pedro ^b   Markowitz, Martin ^c   Salomon, Horacio ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Huesped Foundation   (Argentina)

^c ROCKEFELLER UNIVERSITY   (United States)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; POL PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; ARTICLE; CLONE; CONTROLLED STUDY; DRUG SENSITIVITY; GENE AMPLIFICATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATION; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; SPECIES; TREATMENT FAILURE; VIROGENESIS; VIRUS INFECTION; ADULT; CLASSIFICATION; DNA SEQUENCE; DRUG ADMINISTRATION; DRUG EFFECT; ENZYMOLOGY; FEMALE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MOLECULAR EVOLUTION; MOLECULAR GENETICS; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; AMINO ACID SEQUENCE; ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; FEMALE; GENE PRODUCTS, ENV; GENE PRODUCTS, POL; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MOLECULAR SEQUENCE DATA; PHYLOGENY; REVERSE TRANSCRIPTASE INHIBITORS; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE;

EID: 0036655272     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.14.7000-7009.2002     Document Type: Article

References (64)

1. Bhattacharyya, D., B. R. Brooks, and L. Callahan. 1996. Positioning of positively charged residues in the V3 loop correlates with HIV type 1 syncytium-inducing phenotype. AIDS Res. Hum. Retrovir. 12:83-90.
2. Boden, D., A. Hurley, L. Zhang, V. Cao, V. Guo, E. Jones, J. Tsay, J. Ip, C. Farthing, K. Limoli, N. Parkin, and M. Markowitz. 1999. HIV-1 drug resistance in newly infected individuals. JAMA 282:1135-1141.
3. Brown, A. J., and A. Cleland. 1996. Independent evolution of the env and pol genes of HIV-1 during zidovudine therapy. AIDS 10:1067-1073.
4. Burke, D. S. 1997. Recombination in HIV: an important viral evolutionary strategy. Emerg. Infect. Dis. 3:253-259.
5. Burland, T. G. 2000. DNASTAR's Lasergene sequence analysis software. Methods Mol. Biol. 132:71-91.
6. a. Centers for Disease Control. 1992. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbid. Mortal. Wkly. Rep. 41:1-19.
7. Cheng-Mayer, C., D. Selo, M. Tateno, and J. A. Levy. 1998. Biologic features of HIV-1 that correlate with virulence in the host. Science 240:80-82.
8. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
9. Connor, R. I., K. E. Sheridan, D. Ceradini, S. Choe, and N. R. Landau. 1997. Change in co-receptor use co-receptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 185:621-628.
10. Croteau, G., L. Doyon, D. Thibeault, G. McKercher, L. Pilote, and D. Lamarre. 1997. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J. Virol. 71:1089-1096.
11. Decks, S. G., T. Wrin, T. Liegler, R. Hoh, M. Hayden, J. D. Barbour, N. S. Hellmann, C. J. Petropoulos, J. M. McCune, M. K. Hellerstein, and R. M. Grant. 2001. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N. Engl. J. Med. 344:472-480.
12. Decks, S. G. 2001. International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J. Acquir. Immune Defic. Syndr. 26(Suppl. 1):S25-S33.
13. Delaugerre, C., M. A. Valantin, M. Mouroux, M. Bonmarchand, G. Carcelain, C. Duvivier, R. Tubiana, A. Simon, F. Bricaire, H. Agut, B. Autran, C. Katlama, and V. Calvez. 2001. Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. AIDS 15:2189-2191.
14. Demeter, L. M., R. W. Shafer, M. Para, G. Morse, W. Freimuth, T. C. Merigan, and R. C. Reichman. 1995. Delavirdine (DLV) susceptibility of HIV-1 isolates obtained from patients receiving DLV monotherapy (ACTG 260). J. Acquir. Immune Defic. Syndr. Hum. Retrovir. 10:23.
15. de Ronde, A., M. van Dooren, L. van Der Hock, D. Bouwhuis, E. de Rooij, B. van Gemen, R. de Boer, and J. Goudsmit. 2001. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J. Virol. 75:595-602.
16. Devereux, H. L., V. C. Emery, M. A. Johnson, and C. Loveday. 2001. Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations. J. Med. Virol. 65:218-224.
17. Devereux, H. L., M. Youle, M. A. Johnson, and C. Loveday. 1999. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 13:F123-F127.
18. Eigen, M., and C. K. Biebricher. 1998. Sequence space and quasispecies distribution, p. 3-22. In E. Domingo, J. J. Holland, and P. Ahlquist (ed.), RNA genetics, vol. III. CRC Press, Inc., Boca Raton, Fla.
19. Felsenstein, J. 1985. Confidence limits on phylogenies: an approach using the bootstrap. Evolution 29:783-791.
20. Goudsmit, J., A. de Ronde, E. de Rooij, and R. de Boer. 1997. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215. J. Virol. 71:4479-4484.
21. Goudsmit, J., A. De Ronde, D. D. Ho, and A. S. Perelson. 1996. Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase. J. Virol. 70:5662-5664.
22. Hammond, A. L., J. Lewis, J. May, J. Albert, P. Balfe, and J. A. McKeating. 2001. Antigenic variation within the CD4 binding site of human immunodeficiency virus type 1 gp120: effects on chemokine receptor utilization. J. Virol. 75:5593-5603.
23. Harrigan, P. R., S. Bloor, and B. A. Larder. 1998. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J. Virol. 72:3773-3778.
24. Holland, J. J., J. C. De La Torre, and D. A. Steinhauer. 1992. RNA virus populations as quasispecies. Curr. Top. Microbiol. Immunol. 176:1-20.
25. Hung, C. S., N. Vander Heulen, and L. Ratner. 1999. Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization. J. Virol. 73:8216-8226.
26. Imamichi, T., S. C. Berg, H. Imamichi, J. C. Lopez, J. A. Metcalf, J. Falloon, and H. C. Lane. 2000. Relative replication fitness of a high-level 3′-azido-3′-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr->Gly) at codon 69. J. Virol. 74:10958-10964.
27. Izopet, J., P. Massip, C. Soujris, K. Sandres, B. Puissant, M. Obadia, C. Pasquier, E. Bonnet, B. Marchou, and J. Puel. 2000. Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen. AIDS 14:2247-2255.
28. Kantor, R., R. Machekano, M. J. Gonzales, K. Dupnik, J. M. Shapiro, and R. W. Shafer. 2001. Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: an expanded data model integrating natural language text and sequence analysis programs. Nucleic Acids Res. 29:296-299.
29. Karlsson, A., K. Parsmyr, E. Sandstrom, E. M. Fenyo, and J. Albert. 1994. MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. J. Clin. Microbiol. 32:354-370.
30. Kaye, S., E. Comber, M. Tenant-Flowers, and C. Loveday. 1995. The appearance of drug resistance-associated point mutations in HIV type 1 plasma RNA precedes their appearance in proviral DNA. AIDS Res. Hum. Retrovir. 11:1221-1225.
31. Kijak, G. H., S. E. Pampuro, M. M. Avila, C. Zala, P. Cahn, M. A. Wainberg, and H. Salomon. 2001. Resistance profiles to antiretroviral drugs in HIV-1 drug-naive patients in Argentina. Antivir. Ther. 6:71-77.
32. Kimura, M. 1980. A simple method for estimating evolutionary rate of base substitutions through comparative studies of nucleotide sequences. J. Mol. Evol. 16:111-120.
33. Koch, N., N. Yahi, F. Ariasi, J. Fantini, and C. Tamalet. 1999. Comparison of human immunodeficiency virus type 1 (HIV-1) protease mutations in HIV-1 genomes detected in plasma and in peripheral blood mononuclear cells from patients receiving combination drug therapy. J. Clin. Microbiol. 37:1595-1597.
34. Korber, B. T., B. T. Foley, C. L. Kuiken, et al. 1998. Numbering positions in HIV relative to HXB2CG, p. III-102-III-111. In B. Korber, B. Hahn, B. Foley, F. McCutchan, C. Kuiken, J. W. Mellors, and J. Soroski (ed.), Human retroviruses and AIDS 1998: a compilation and analysis of nucleic acid and amino acid sequences. Los Alamos Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, N.M.
35. Kosalaraksa, P., M. F. Kavlick, V. Maroun, R. Le, and H. Mitsuya. 1999. Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay. J. Virol. 73:5356-5363.
36. Kozal, M. J., R. W. Shafer, M. A. Winters, D. A. Katzenstein, and T. C. Merigan. 1993. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J. Infect. Dis. 167:526-532.
37. Kumar, S., K. Tamura, I. B. Jakobsen, and M. Nei. 2001. MEGA2: molecular evolutionary genetics analysis software. Bioinformatics 17:1244-1245.
38. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1158.
39. Loveday, C., S. Kaye, M. Tenant-Flowers, M. Semple, U. Ayliffe, I.V. Weller, and R. S. Tedder. 1995. HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy. Lancet 345:820-824.
40. Loveday, C. 2001. International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance. J. Acquir. Immune Defic. Syndr. 26(Suppl. 1):S10-S24.
41. Maeda, Y., D. J. Venzon, and H. Mitsuya. 1998. Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. J. Infect. Dis. 177: 1207-1213.
42. Mansky, L. M., and H. M. Temin. 1995. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69:5087-5094.
43. Martinez-Picado, J., A. V. Savara, L. Shi, L. Sutton, and R. T. D'Aquila. 2000. Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants. Virology 275:318-322.
44. Martinez-Picado, J., A. V. Savara, L. Sutton, and R. T. D'Aquila. 1999. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J. Virol. 73:3744-3752.
45. McKeating, J. A., C. Shotton, J. Cordell, S. Graham, P. Balfe, N. Sullivan, M. Charles, M. Page, A. Bolmstedt, S. Olofsson, et al. 1993. Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120. J. Virol. 67:4932-4944.
46. Miller, V., C. Sabin, K. Hertogs, S. Bloor, J. Martinez-Picado, R. D'Aquila, B. Larder, T. Lutz, P. Gute, E. Weidmann, H. Rabenau, A. Phillips, and S. Staszewski. 2000. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 14:2857-2867.
47. Miller, V. 2001. International perspectives on antiretroviral resistance. Resistance to protease inhibitors. J. Acquir. Immune Defic. Syndr. 26(Suppl. 1):S34-S50.
48. Page, R. D. M., and E. C. Holmes. 1998. Molecular evolution. A phylogenetic approach. Blackwell Science Ltd., Oxford, United Kingdom.
49. Page, R. D. M. 1996. TREEVIEW: an application to display phylogenetic trees on personal computers. Comput. Appl. Biosci. 12:53-60.
50. Parikh, U., J. Hammond, C. Calef, B. Larder, R. Schinazi, and J. Mellors. 2000. Mutations in retroviral genes associated with drug resistance, p.106-161. In C. Kuiken, B. Foley, B. Hahn, P. Marx, F. McCutchan, J. Mellors, J. Mullins, S. Wolinsky, and B. Korber (ed.), HIV sequence compendium 2000. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, N.M.
51. Perelson, A. S., A. U. Neumann, M. Markowitz, J. M. Leonard, and D. D. Ho. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586.
52. Price, R. W., E. E. Paxinos, R. M. Grant, et al. 2001. Cerebrospinal fluid response to structured treatment interruption after virological failure. AIDS 15:1251-1259.
53. Richman, D., C. K. Shih, I. Lowy, J. Rose, P. Prodanovich, S. Goff, and J. Griffin. 1991. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl. Acad. Sci. USA 88:11241-11245.
54. Saitou, N., and M. Nei. 1987. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4:406-425.
55. Salomon, H., A. Belmonte, K. Nguyen, Z. Gu, M. Gelfand, and M. A. Wainberg. 1994. Comparison of cord blood and peripheral blood mononuclear cells as targets for viral isolation and drug sensitivity studies involving human immunodeficiency virus type 1. J. Clin. Microbiol. 32:2000-2002.
56. Sarmati, L., E. Nicastri, S. G. Parisi, G. D'Ettorre, P. Narciso, G. Mancino, I. Gallo, V. Abbadessa, N. E. Dalle, C. Traina, V. Vullo, and M. Andreoni. 2001. Failure of stavudine-lamivudine combination therapy in antiretroviral-naïve patients with AZT-like HIV-1 resistance mutations. J. Med. Virol. 65:631-636.
57. Schuitemaker, H., M. Koot, N. A. Kootstra, M. W. Dercksen, R. E. de Goede, R. P. van Steenwijk, J. M. Lange, J. K. Schattenkerk, F. Miedema, and M. Tersmette. 1992. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J. Virol. 66:1354-1360.
58. Smith, M. S., K. L. Koerber, and J. S. Pagano. 1993. Zidovudine-resistant human immunodeficiency virus type 1 genomes detected in plasma distinct from viral genomes in peripheral blood mononuclear cells. J. Infect. Dis. 167:445-448.
59. Thompson, J. D., D. G. Higgins, and T. J. Gibson. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:4673-4680.
60. Verhofstede, C., F. V. Wanzeele, B. Van Der Gucht, N. DeCabooter, and J. Plum. 1999. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS 13:2541-2546.
61. Winslow, D. L., S. Garber, C. Reid, H. Scarnati, D. Baker, M. M. Rayner, and E. D. Anton. 1996. Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266. AIDS 10:1205-1209.
62. Yerly, S., A. Rakik, S. K. De Loes, B. Hirschel, D. Descamps, F. Brun-Vezinet, and L. Perrin. 1998. Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants. J. Virol. 72:3520-3523.
63. Zhang, L., B. Ramratnam, K. Tenner-Racz, Y. He, M. Vesanen, S. Lewin, A. Talal, P. Racz, A. S. Perelson, B. T. Korber, M. Markowitz, and D. D. Ho. 1999. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N. Engl. J. Med. 340:1605-1613.
64. Zhang, Y. M., S. C. Dawson, D. Landsman, H. C. Lane, and N. P. Salzman. 1994. Persistence of four related human immunodeficiency virus subtypes during the course of zidovudine therapy: relationship between virion RNA and proviral DNA. J. Virol. 68:425-432.